| Drug Name |
Arsenic trioxide |
| Drug ID |
BADD_D00169 |
| Description |
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide. |
| Indications and Usage |
For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XX27 |
| DrugBank ID |
DB01169
|
| KEGG ID |
D02106
|
| MeSH ID |
D000077237
|
| PubChem ID |
14888
|
| TTD Drug ID |
D07VIK
|
| NDC Product Code |
64743-400; 14789-600; 49315-007; 54973-0605; 68428-033; 70710-1610; 43406-0168; 49315-005; 68083-462; 68428-225; 64757-0001; 23155-870; 0220-0522; 0220-0527; 0220-0549; 70710-1896; 55150-366; 25021-226; 43406-0318; 0220-0554; 0220-0557; 63323-637; 81607-005; 64757-0016; 0220-0528; 54879-027; 62106-4878; 58621-001; 0220-0530; 68428-083; 70710-1895; 0220-0553; 63459-601; 69918-720; 70121-1483; 76472-3004; 81607-006; 72659-245; 0220-0526; 50742-438; 68083-535; 0781-3498; 54875-0005; 23155-869; 25021-227; 0220-0525; 0220-0550; 68382-997; 70121-1658; 70860-217; 76472-1132; 76472-4004; 0220-0529 |
| UNII |
S7V92P67HO
|
| Synonyms |
Arsenic Trioxide | As2O3 | Arsenous Anhydride | Diarsenic Trioxide | Arsenic Oxide (As2O3) | Arsenic(III) Oxide | Tetraarsenic Oxide | Arsenolite | As4O6 | Tetra-Arsenic Oxide | Tetra Arsenic Oxide | Tetraarsenic Hexaoxide | Arsenic Oxide (As4O6) | Tetra-Arsenic Hexaoxide | Tetra Arsenic Hexaoxide | Naonobin | Trisenox | Trixenox |
